Page last updated: 2024-12-09

1-(4-fluorophenyl)-7-(4-methylphenyl)-5,5-bis(trifluoromethyl)-8H-pyrimido[4,5-d]pyrimidine-2,4-dione

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You're asking about a specific chemical compound, **1-(4-fluorophenyl)-7-(4-methylphenyl)-5,5-bis(trifluoromethyl)-8H-pyrimido[4,5-d]pyrimidine-2,4-dione**. This compound is a derivative of pyrimido[4,5-d]pyrimidine, which is a heterocyclic ring system found in many biologically active molecules.

**Why it's Important for Research:**

While I can't provide specific research findings without more context, this type of compound is likely being investigated for its potential medicinal properties. Here's why:

* **Pyrimidine derivatives are often bioactive:** Pyrimidines are found in essential biological molecules like DNA and RNA. Their derivatives are often explored for their potential to interact with biological targets and exhibit therapeutic effects.
* **Fluorine substitution:** The presence of fluorine atoms in the molecule can enhance its pharmacokinetic properties, making it more easily absorbed by the body and potentially improving its effectiveness.
* **Trifluoromethyl groups:** The trifluoromethyl groups are known to modify the electronic properties of the molecule, influencing its interactions with biological targets.
* **Structure-activity relationships:** Researchers often synthesize and study compounds like this to understand how changes in molecular structure influence their biological activity. This helps them develop more potent and selective drugs.

**Possible Research Areas:**

Given its structure, the compound you mentioned could be relevant to research in various areas, including:

* **Anti-cancer agents:** Pyrimidine derivatives are known to have anti-cancer activity, potentially by interfering with DNA replication or cell signaling pathways.
* **Anti-inflammatory agents:** Some pyrimidine derivatives have anti-inflammatory effects.
* **Anti-viral agents:** Compounds like this may have antiviral properties, potentially inhibiting the replication of viruses.
* **Other therapeutic areas:** The specific structure of the compound suggests it might have activity in other areas like cardiovascular disease, neurological disorders, or metabolic diseases.

**Finding More Information:**

To learn more about the specific research being conducted with this compound, you would need additional information:

* **The research group or publication:** Look for articles or publications specifically mentioning this compound.
* **Clinical trials or patents:** Search for clinical trials or patent information related to this compound.

Remember, research is an ongoing process, and the significance of a compound like this can evolve as new findings emerge.

Cross-References

ID SourceID
PubMed CID1623337
CHEMBL ID1388753
CHEBI ID111205

Synonyms (17)

Synonym
smr000220298
MLS000580885 ,
1-(4-fluoro-phenyl)-7-p-tolyl-5,5-bis-trifluoromethyl-5,8-dihydro-1h-pyrimido[4,5-d]pyrimidine-2,4-dione
CHEBI:111205
1-(4-fluorophenyl)-7-(4-methylphenyl)-5,5-bis(trifluoromethyl)-8h-pyrimido[4,5-d]pyrimidine-2,4-dione
AKOS001683806
AKOS005494736
STK770746
1-(4-fluorophenyl)-7-(4-methylphenyl)-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1h,3h)-dione
HMS2523L24
1-(4-fluorophenyl)-4-hydroxy-7-(4-methylphenyl)-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one
STK568834
MLS003903459
1-(4-fluorophenyl)-7-(4-methylphenyl)-5,5-bis(trifluoromethyl)-1h,2h,3h,4h,5h,8h-pyrimido[4,5-d][1,3]diazine-2,4-dione
CHEMBL1388753
Q27190818
cid 1623337
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
pyrimidopyrimidineAn organic heterobicyclic compound with a skeleton consisting of two pyrimidine rings that are ortho-fused to each other at any position.
monofluorobenzenesAny member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying a single fluorine substitutent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency0.89130.177814.390939.8107AID2147
glp-1 receptor, partialHomo sapiens (human)Potency3.16230.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency94.56250.100020.879379.4328AID588453; AID588456
ATAD5 protein, partialHomo sapiens (human)Potency23.10930.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency23.10930.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency10.00000.00527.809829.0929AID588855
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency35.48130.011212.4002100.0000AID1030
PINK1Homo sapiens (human)Potency39.81072.818418.895944.6684AID624263
67.9K proteinVaccinia virusPotency11.29470.00018.4406100.0000AID720579; AID720580
ParkinHomo sapiens (human)Potency39.81070.819914.830644.6684AID624263
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency44.66840.036619.637650.1187AID1466; AID2242
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency20.59620.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency50.11873.548119.542744.6684AID743266
huntingtin isoform 2Homo sapiens (human)Potency14.12540.000618.41981,122.0200AID1688
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency11.22020.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency24.84460.004611.374133.4983AID624296; AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency35.48130.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency44.66843.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency44.66843.548118.039535.4813AID1466
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]